Cell therapies via large-scale culture of pluripotent stem cells

Purpose and goal

Increased sales of our future growth medium, more efficient production of our current products, more collaborations with clinical specialization and accumulation of marketing materials to attract potential customers both for the sale of media and partners in clinical research.

Results and expected effects

The project has exceeded expectations, largely thanks to the opportunities to cooperate with external partners (iBET, Portugal). Data from the project have already been used in poster for marketing purposes (see Annex 1). The results obtained in the Bioreactor experiments are compiled in iBETs final report (see Annex 2). Takara Bio Europe AB will use the information partly as marketing materials, but also as a valuable basis for decisions on future investments regarding the scaling up of stem cells for therapy projects.

Approach and implementation

According to described phase 1-2 in the project plan has Takara studied possible bioreactors and further optimized cultivation in bioreactor under phase 3. Below is a brief summary of progression. 1) Contract with iBET ended with very satisfactory results - see Annex 2 2) Established scaled-medium manufacturing 3) Optimization of the medium for 3D suspension cultures 4) Validation of stabilizing measures for 3D culture 5) Validation of several cell lines in suspension culture experiments 6) Validation of the freeze/thaw protocols